ZA201708223B - Endostatin fragments and variants for use in treating fibrosis - Google Patents
Endostatin fragments and variants for use in treating fibrosisInfo
- Publication number
- ZA201708223B ZA201708223B ZA2017/08223A ZA201708223A ZA201708223B ZA 201708223 B ZA201708223 B ZA 201708223B ZA 2017/08223 A ZA2017/08223 A ZA 2017/08223A ZA 201708223 A ZA201708223 A ZA 201708223A ZA 201708223 B ZA201708223 B ZA 201708223B
- Authority
- ZA
- South Africa
- Prior art keywords
- variants
- treating fibrosis
- endostatin fragments
- endostatin
- fragments
- Prior art date
Links
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 title 1
- 108010079505 Endostatins Proteins 0.000 title 1
- 206010016654 Fibrosis Diseases 0.000 title 1
- 230000004761 fibrosis Effects 0.000 title 1
- 239000012634 fragment Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562171889P | 2015-06-05 | 2015-06-05 | |
| US201562257607P | 2015-11-19 | 2015-11-19 | |
| PCT/US2016/035858 WO2016197018A1 (en) | 2015-06-05 | 2016-06-03 | Endostatin fragments and variants for use in treating fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201708223B true ZA201708223B (en) | 2018-11-28 |
Family
ID=56236074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2017/08223A ZA201708223B (en) | 2015-06-05 | 2017-12-04 | Endostatin fragments and variants for use in treating fibrosis |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10844392B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3303383A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6952685B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20180033499A (cg-RX-API-DMAC7.html) |
| CN (2) | CN107849117B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2016270428B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112017026209A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2988299C (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016197018A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201708223B (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016197018A1 (en) * | 2015-06-05 | 2016-12-08 | Ibio, Inc. | Endostatin fragments and variants for use in treating fibrosis |
| AU2019338416A1 (en) * | 2018-09-14 | 2021-04-29 | Akso Biopharmaceutical, Inc. | sPD-1 variant - Fc fusion proteins |
| WO2021007094A1 (en) * | 2019-07-10 | 2021-01-14 | Musc Foundation For Research Development | Endostatin peptides for the treatment of tumors, fibrosis and acute lung injury |
| US12454551B2 (en) * | 2019-07-31 | 2025-10-28 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Peptides as inhibitors of fibrotic matrix accumulation |
| JP7493945B2 (ja) * | 2020-01-28 | 2024-06-03 | ポーラ化成工業株式会社 | 培養組織の観察方法、培養方法、評価方法及び培養器具 |
| WO2022006601A1 (en) * | 2020-07-02 | 2022-01-06 | Northwestern University | Human recombinant ace2-fc mutants that decouple anti-sars-cov-2 activity from cardiovascular effects |
| US20250195673A1 (en) * | 2020-11-30 | 2025-06-19 | Fred Hutchinson Cancer Center | Compositions and methods for selective depletion of target molecules |
| EP4392056A4 (en) * | 2021-09-07 | 2025-12-24 | Musc Found For Res Dev | Endostatin peptides for the treatment of tumors, fibrosis, and acute lung injury |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US750375A (en) | 1904-01-26 | Potato-digger | ||
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US3832253A (en) | 1973-03-21 | 1974-08-27 | Baxter Laboratories Inc | Method of making an inflatable balloon catheter |
| US4667014A (en) | 1983-03-07 | 1987-05-19 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists |
| US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| IT1164225B (it) | 1983-05-13 | 1987-04-08 | Anic Spa | Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione |
| CA1200416A (en) | 1983-05-13 | 1986-02-11 | Societe Des Produits Nestle S.A. | Food process |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5091309A (en) | 1986-01-16 | 1992-02-25 | Washington University | Sindbis virus vectors |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US5093258A (en) | 1988-08-26 | 1992-03-03 | Therion Biologics Corporation | Recombinant fowlpox virus and recombination vector |
| US5217879A (en) | 1989-01-12 | 1993-06-08 | Washington University | Infectious Sindbis virus vectors |
| US6406697B1 (en) | 1989-02-23 | 2002-06-18 | Genentech, Inc. | Hybrid immunoglobulins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| ES2133271T3 (es) | 1989-07-06 | 1999-09-16 | Univ California | Receptores para factores de crecimiento de fibroblastos. |
| JPH04167172A (ja) | 1990-10-31 | 1992-06-15 | Nec Corp | ベクトルプロセッサ |
| US5756671A (en) | 1994-06-02 | 1998-05-26 | Mitotix, Inc. | CDC37 cell-cycle regulatory protein, and uses related thereto |
| US6080560A (en) * | 1994-07-25 | 2000-06-27 | Monsanto Company | Method for producing antibodies in plant cells |
| US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| US6165460A (en) | 1995-07-10 | 2000-12-26 | Therion Biologics Corporation | Generation of immune responses to prostate-specific antigen (PSA) |
| US5925351A (en) | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
| DE19535939A1 (de) | 1995-09-27 | 1997-04-03 | Agfa Gevaert Ag | Fotografisches Material |
| IL136667A0 (en) | 1997-12-08 | 2001-06-14 | Beth Israel Hospital | Methods of producing anti-angiogenic proteins: endostatin, angiostatin or restin, using a pichia yeast expression system |
| EP1067956B1 (en) | 1998-04-03 | 2007-03-14 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| WO1999062944A2 (en) * | 1998-06-03 | 1999-12-09 | The Children's Medical Center Corporation | Protein oligomer compositions comprising endostatin protein and methods of using the same |
| US6399075B1 (en) | 1998-07-02 | 2002-06-04 | President And Fellows Of Harvard College | Compositions and methods for treating Papillomavirus-infected cells |
| WO2000046350A1 (en) | 1999-02-05 | 2000-08-10 | Thomas Jefferson University | Production of biomedical peptides and proteins in plants using transcomplementation systems |
| US6656728B1 (en) | 1999-02-08 | 2003-12-02 | Chiron Corporation | Fibroblast growth factor receptor-immunoglobulin fusion |
| US7692063B2 (en) * | 2002-11-12 | 2010-04-06 | Ibio, Inc. | Production of foreign nucleic acids and polypeptides in sprout systems |
| ES2531125T3 (es) | 2003-02-03 | 2015-03-10 | Ibio Inc | Sistema para la expresión de genes en plantas |
| US20060024272A1 (en) * | 2004-07-29 | 2006-02-02 | Large Scale Biology Corporation | C-terminally truncated interferon |
| JP2010531666A (ja) * | 2007-06-26 | 2010-09-30 | ユニバーシティ オブ マイアミ | 抗体−エンドスタチン融合タンパク質及びそのバリアント |
| WO2011050311A1 (en) | 2009-10-22 | 2011-04-28 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Use of endostatin peptides for the treatment of fibrosis |
| BR112014001268A2 (pt) * | 2011-07-19 | 2017-02-21 | Thrasos Innovation Inc | peptídeos antifibróticos e seu uso em métodos para tratamento de doenças e distúrbios caracterizados por fibrose |
| WO2016197018A1 (en) | 2015-06-05 | 2016-12-08 | Ibio, Inc. | Endostatin fragments and variants for use in treating fibrosis |
-
2016
- 2016-06-03 WO PCT/US2016/035858 patent/WO2016197018A1/en not_active Ceased
- 2016-06-03 CN CN201680044858.5A patent/CN107849117B/zh active Active
- 2016-06-03 EP EP16732386.4A patent/EP3303383A1/en not_active Withdrawn
- 2016-06-03 JP JP2018515195A patent/JP6952685B2/ja not_active Expired - Fee Related
- 2016-06-03 CN CN202210968572.3A patent/CN115925878A/zh active Pending
- 2016-06-03 US US15/579,690 patent/US10844392B2/en not_active Expired - Fee Related
- 2016-06-03 AU AU2016270428A patent/AU2016270428B2/en not_active Ceased
- 2016-06-03 CA CA2988299A patent/CA2988299C/en active Active
- 2016-06-03 BR BR112017026209A patent/BR112017026209A2/pt not_active Application Discontinuation
- 2016-06-03 KR KR1020187000354A patent/KR20180033499A/ko not_active Ceased
-
2017
- 2017-12-04 ZA ZA2017/08223A patent/ZA201708223B/en unknown
-
2020
- 2020-11-09 US US17/092,539 patent/US11912755B2/en active Active
-
2021
- 2021-02-05 AU AU2021200765A patent/AU2021200765B2/en not_active Ceased
- 2021-09-28 JP JP2021158128A patent/JP7404320B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021200765A1 (en) | 2021-03-04 |
| AU2016270428A1 (en) | 2018-01-25 |
| WO2016197018A1 (en) | 2016-12-08 |
| EP3303383A1 (en) | 2018-04-11 |
| CN107849117B (zh) | 2022-08-26 |
| CN107849117A (zh) | 2018-03-27 |
| JP2022002527A (ja) | 2022-01-11 |
| US20180179263A1 (en) | 2018-06-28 |
| CN115925878A (zh) | 2023-04-07 |
| JP6952685B2 (ja) | 2021-10-20 |
| AU2016270428B2 (en) | 2020-11-26 |
| US20210108221A1 (en) | 2021-04-15 |
| CA2988299A1 (en) | 2016-12-08 |
| US11912755B2 (en) | 2024-02-27 |
| JP7404320B2 (ja) | 2023-12-25 |
| WO2016197018A9 (en) | 2017-01-19 |
| BR112017026209A2 (pt) | 2018-11-27 |
| WO2016197018A8 (en) | 2017-07-13 |
| JP2018524019A (ja) | 2018-08-30 |
| KR20180033499A (ko) | 2018-04-03 |
| AU2021200765B2 (en) | 2023-04-13 |
| US10844392B2 (en) | 2020-11-24 |
| CA2988299C (en) | 2023-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL278062B (en) | Plasma kallikrein-binding proteins and their uses in the treatment of hereditary angioedema | |
| ZA201708223B (en) | Endostatin fragments and variants for use in treating fibrosis | |
| IL259570A (en) | Combined therapy and their uses and methods | |
| GB201509086D0 (en) | Process for removing chloropropanols and/or glycidol | |
| IL251215A0 (en) | Cannabinoid preparation and method for treating pain | |
| IL236739B (en) | Antenna formed from plates and methods useful in conjunction therewith | |
| IL251759A0 (en) | Preparations and methods for treating insomnia | |
| GB201511382D0 (en) | Novel compounds and their use in therapy | |
| ZA202108599B (en) | Anti-tnfalpha-antibodies and functional fragments thereof | |
| SG11202000029PA (en) | Anti-tnfalpha-antibodies and functional fragments thereof | |
| IL257820A (en) | Aminoglycosides for the treatment of genetic diseases | |
| GB201621394D0 (en) | Improvements in and relating to waste treatment | |
| IL250980A0 (en) | Mucolytic agents for use in the treatment of pulmonary sarcoidosis | |
| IL247938A0 (en) | Onconas for use in the treatment or prevention of viral infections | |
| IL261261A (en) | Antibodies against tnf-alpha and functional fragments thereof | |
| IL261098A (en) | Antibodies against tnf-alpha and functional fragments thereof | |
| IL259358A (en) | Bis-pyridazine compounds and their use in treating cancer | |
| PT3406258T (pt) | Medicamento para utilização no tratamento de gota | |
| IL261793A (en) | Anti-tnfalpha antibodies and their functional parts | |
| GB201502983D0 (en) | Composition and process | |
| EP3271464A4 (en) | Mirna mimetics and their use in treating sensory conditions | |
| EP3110453A4 (en) | Tmem100 peptides and variants thereof and their use in treating or preventing diseases or conditions | |
| SG11201804140PA (en) | Acidic-gas treating agent and acidic-gas treating method | |
| GB201510764D0 (en) | bis-Pyridazine compounds and their use in treating cancer | |
| GB201511158D0 (en) | Cell modification and application in therapy |